GlassScriptPhysician profile
Charisma K Bailey
NPI 1801200506
$4,328.66
in general payments reported to CMS, 2019-2025
27 companies · $785 in 2025
The $785 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,072 · 2022: $947 · 2023: $727 · 2024: $798 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,207.92 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,067.24 | 2021-2025 | Lifevest |
| Abbott Laboratories | $381.70 | 2021-2025 | Accent, Aveir, Gallant |
| Janssen Pharmaceuticals, INC | $248.97 | 2021-2024 | Xarelto |
| Medtronic, INC. | $241.28 | 2021-2025 | Linq II |
| Atricure, INC. | $181.06 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $155.47 | 2021-2024 | Farxiga |
| Boston Scientific Corporation | $139.95 | 2021-2025 | Watchman Access System, Watchman Flx |
| Novo Nordisk INC | $74.56 | 2022 | |
| Irhythm Technologies, INC. | $67.40 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $62.70 | 2021 | |
| Ironwood Pharmaceuticals, INC | $54.22 | 2024 | |
| Cardiva Medical, INC. | $53.31 | 2025 | Optowire |
| Cardiovascular Systems INC. | $47.88 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.14 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.14 | 2022-2023 | Injectafer |
| Amarin Pharma, INC. | $36.04 | 2021 | |
| Tactile Systems Technology INC | $33.73 | 2025 | Flexitouch Plus, Nimbl |
| Actelion Pharmaceuticals US, INC. | $30.88 | 2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $24.39 | 2024 | Arcalyst |
| Convatec INC. | $22.81 | 2022 | |
| Merck Sharp & Dohme LLC | $22.52 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $19.70 | 2023 | Arcalyst |
| Amgen INC. | $18.81 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.57 | 2023 | Ocaliva |
| Lexicon Pharmaceuticals, INC. | $15.00 | 2024 | |
| Altathera Pharmaceuticals LLC | $14.27 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charisma Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.